NPIP is created and delivered by internationally renowned experts in medicine, science, and academia.

As part of UKRI, MRC is at the forefront of scientific discovery to improve human health. MRC’s scientists tackle some of the greatest health problems facing humanity in the 21^st Century, from the rising tide of chronic disease associated with ageing, to the threats posed by rapidly mutating micro-organisms. MRC is a key partner in NPIP overseeing the UKRI Infrastructure funding and ensuring it delivers the full potential this new investment offers the UK.

As a national independent innovation centre, MDC transforms great UK science into better treatments for patients. Through NPIP, MDC hopes to reshape the nature of drug discovery and make it easier for innovators to turn their ideas into novel therapeutics and diagnostics. It offers world-class expertise, facilities, and advanced analytics so, together, it can accelerate development, streamline pathways to commercialisation, and ultimately improve patient outcomes.

MDC can also help breathe new energy into the Life Sciences ecosystem by connecting stakeholders and experts across the health innovation landscape, both nationally and internationally.

Innovate UK, the national innovation agency, drives transformational change in health innovation to enable people to live longer healthy lives, and realise the UK’s position as a world-leader in Life Sciences.

Innovate UK drives productivity and economic growth by supporting businesses through a wide spectrum of activities, including funding initiatives, facilitating invaluable connections among innovators and sectors, championing public-private partnerships, and fostering international collaborations.

Innovate UK will play a key role in building a national ecosystem around total-body PET imaging that uncovers ideas and accelerates new discoveries.

The University of Cambridge is one of the world’s most prestigious institutions, renowned for its rigorous academic standards and centuries-long tradition of excellence. Reflecting its commitment to advancing research and driving innovation, Cambridge is now home to a total-body PET scanner, broadening the geographic reach of NPIP through the ANGLIA network with University College London and University of Sheffield and providing better access to patients from East Anglia and the Midlands.

Imperial College London is a global top-ten university with a world-class reputation and world-leading research. Its students and staff are working to solve some of the biggest challenges in science, medicine, engineering and business. As part of NPIP, Imperial will work with partners to drive the development of the platform for clinical research.

The King’s College London & Guy’s and St Thomas’ Hospital PET Centre is embedded within the School of Biomedical Engineering & Imaging Sciences (BMEIS) at King’s.

The King’s College London aims to deliver maximum value to the UK through total-body PET in an environment that is readily accessible to the UK’s research community, located within a leading NHS hospital, and surrounded by complementary facilities and expertise.

The University of Edinburgh has had an extraordinary influence on the world and on individual lives for more than 400 years. Each year, The University of Edinburgh takes on tomorrow’s greatest challenges; applying new research in new ways to solve new problems.

Working closely with partners at The University of Glasgow, The University of Edinburgh will co-manage Scotland’s first-of-its-kind total-body PET scanner that will transform medical research and benefit patients.

As one of the top 100 of the world’s universities, The University of Glasgow delivers world-class, world-changing research and education with impact. The University of Glasgow is currently investing £1 billion in its estate to create spaces and opportunities that will allow the university to remain at the forefront of change, excellence and innovation.

Working closely with partners at The University of Edinburgh, The University of Glasgow will co-manage Scotland’s first-of-its-kind total-body PET scanner that will transform medical research and benefit patients.

The Royal Free London’s mission is to provide world-class expertise and local care.

We attract patients from across the country and beyond to our specialist services in liver and kidney transplantation, haemophilia, HIV, infectious diseases, plastic surgery, immunology, neurology, Parkinson’s disease, vascular surgery, cardiology, amyloidosis and scleroderma. We are a member of the academic health science partnership UCL Partners, which brings people and organisations together to transform the health and wellbeing of the population.

The Royal Free London is one of four trusts across the NHS to be chosen to develop a group model enabling us to share services and resources more effectively across hospitals to improve the experience of patients and staff.

Barnet Hospital, Chase Farm Hospital, North Middlesex University Hospital and the Royal Free Hospital are part of the Royal Free London group.

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere.

As a leading medical technology company, Siemens Healthineers is committed to enabling high-quality, efficient care. Equipped with technical precision that redefines the boundaries of molecular imaging and optimises operational performance, Biograph Vision Quadra Total-body PET/CT scanners from Siemens Healthineers are set to support NPIP in unlocking a range of clinical and research opportunities.

University of Sheffield is a world top 100 university with a global repartition for its exceptional teaching, impactful research, international outlook and outstanding student experience. It hosts the Sheffield Institute of Translational Neuroscience (SITran), which is a world leader in many unique clinical research areas such as motor neuron disease and neurodegenerative disorders. Working with Cambridge and UCL, Sheffield develops world class research using the new total-body PET platform.